



**Press Release**  
**21 April 2008**

## **BioGaia signs agreement for Belgium and Luxembourg**

**BioGaia has signed a distribution agreement with the Belgium company NeoCare which gives NeoCare rights to sell BioGaia's Probiotic drops and tablets in Belgium and Luxembourg. The products will be sold under BioGaia's trademark.**

NeoCare is a pharmaceutical company, operational in Belgium, building a unique partnership philosophy in the choice of products which are generally recognised for their absolute and proven top quality.

"The agreement with NeoCare proves that we have a very competitive product portfolio appealing to companies with focus on pharmacies and health care stakeholders", says PR President BioGaia AB.

"The products will be the first probiotic product-range in Belgium and Luxembourg, offered under the special pharmaceutical form of drops (indicated for infants) and chewable tablets", says Jef Hus, General Manager NeoCare.

### **Latest press releases from BioGaia:**

2008-03-19	Notice of Annual General Meeting of BioGaia
2008-02-20	BioGaia signs new agreement with Ferring Pharmaceuticals
2008-02-13	Year-end report

For additional information contact:

Peter Rothschild, President, telephone: +46 8 - 555 293 00,  
Jan Annwall, Executive vice President, telephone: +46 8 - 555 293 00

---

***BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm.***  
***www.biogaia.com***